Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer's disease.
Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.
Results: Rates of discontinuation due to any reason or adverse events were similar between groups. Incidences of gastrointestinal adverse events were 3.8% in the immediate and 0.8% in the delayed switch group. No patients discontinued secondary to nausea and vomiting. Discontinuations due to application site reactions were low (2.3%). Asymptomatic bradycardia was more common following the immediate switch (2.3% vs 0%); however, these patients had coexisting cardiac comorbidities.
Conclusion: Both switch strategies were safe and well tolerated. The majority of patients may be able to switch directly to rivastigmine patches without a withdrawal period. Appropriate clinical judgment should be used for patients with existing bradycardia or receiving beta blockers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846161 | PMC |
| http://dx.doi.org/10.1177/1533317509333037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Changes in dementia treatment patterns associated with changes in the National Policy in South Korea among patients with newly diagnosed Alzheimer's disease between 2011 and 2017: results from the multicenter, retrospective CAPTAIN study.
BMC Public Health
January 2024
National Health Insurance Service Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea.
Article Synopsis
- - The South Korean government has been implementing strategies since 2008 to combat dementia, including expanding long-term care insurance (LTCI) eligibility for people with dementia in 2014, which provided better access to care services.
- - A study of 3,997 newly diagnosed Alzheimer's patients from 17 hospitals compared treatment patterns before (Cohort 1) and after (Cohort 2) the LTCI revision, revealing that Cohort 2 had a longer duration of initial treatment and lower treatment discontinuation rates.
- - Despite similar cognitive scores at diagnosis, patients from Cohort 2 showed improved treatment outcomes, indicating that the revised LTCI system positively influenced care for Alzheimer's patients in South Korea. *
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD).
BMC Neurol
November 2023
Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA, 19486, USA.
Background: Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries.
Methods: The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.
Behavioural Variant Frontotemporal Dementia due to Gene Mutation: A Case Report.
Curr Alzheimer Res
November 2023
The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Background: Frontal, temporal lobe dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative diseases. Studies have found that mutations have been found in patients with familial and sporadic ALS and FTD. Behavioural variant frontotemporal dementia (bvFTD) is a clinical syndrome characterized by progressive deterioration of personality, social behaviour, and cognitive function, which is most closely related to genetic factors.
View Article and Find Full Text PDFLong-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer's Disease.
J Alzheimers Dis
October 2023
Teikoku Seiyaku Co., Ltd., Kagawa, Japan.
Background: Oral formulations are not suitable for demented patients with dysphagia, those refuse to take tablets, or those with drug compliance problem. However, only oral formulations of donepezil hydrochloride are approved for the treatment of severe Alzheimer's disease in Japan.
Objective: To evaluate the safety, tolerability, and efficacy of long-term application of a 55.
A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients.
PLoS One
September 2023
Schmid College of Science and Technology, Chapman University, Orange, CA, United States of America.
Alzheimer's disease is the most common type of dementia that currently affects over 6.5 million people in the U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!